in the UK they have a body called NICE which regulates treatments based on cost-effectiveness (because the NHS is a public body). So that makes sense to a point but this is a new disease for which the treatment is pennies. No time to do a full investigation and clinical review and in any case the budget is nothing. They have previously done extensive reviews for expensive pharma treatments with marginal benefits, which is fine, but this stuff is less than a pound for a course.